In vivo imaging as a Pharmacodynamic marker

Clinical Cancer Research

Volumn 20, Issue 10, 2014, Pages 2569-2577

  Van Der Veldt, Astrid A M ^a,b   Lammertsma, Adriaan A ^b  

^a Departments of Internal Medicine and Geriatric Medicine   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CABAZITAXEL; DOCETAXEL; DOCETAXEL C 11; PACLITAXEL F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CARBON; FLUORINE; PACLITAXEL; TAXOID;

ABSENCE OF SIDE EFFECTS; ARTICLE; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SYNTHESIS; DRUG TRANSPORT; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; IN VIVO STUDY; ISOTOPE LABELING; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR WEIGHT; NONHUMAN; PHARMACODYNAMICS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIOTHERAPY PLANNING SYSTEM; METABOLISM; NEOPLASMS; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARBON RADIOISOTOPES; FLUORINE RADIOISOTOPES; HUMANS; NEOPLASMS; PACLITAXEL; POSITRON-EMISSION TOMOGRAPHY; TAXOIDS; TISSUE DISTRIBUTION; TREATMENT OUTCOME;

EID: 84901049538     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2666     Document Type: Article

References (72)

1. van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA, Hendrikse NH. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr Pharm Des 2008;14:2914-31.
2. Nicolaou KC, Yang Z, Liu JJ, Ueno H, Nantermet PG, Guy RK, et al. Total synthesis of taxol. Nature 1994;367:630-4.
3. Stierle A, Strobel G, Stierle D. Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science 1993;260:214-6.
4. Yared JA, Tkaczuk KH. Update on taxane development: new analogs and new formulations. Drug Des Devel Ther 2012;6:371-84.
5. Ganansia-Leymarie V, Bischoff P, Bergerat JP, Holl V. Signal transduction pathways of taxanes-induced apoptosis. Curr Med Chem Anticancer Agents 2003;3:291-306.
6. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7.
7. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
8. Ravdin PM, Burris HA III, Cook G, Eisenberg P, Kane M, Bierman WA, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995;13: 2879-85.
9. Valero V, Holmes FA, Walters RS, Theriault RL, Esparza L, Fraschini G, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995;13:2886-94.
10. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in womenwith breast cancer. J Clin Oncol 2005;23:7794-803.
11. de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147-54.
12. Montero A, Fossella F, Hortobagyi G, Valero V. Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol 2005;6:229-39.
13. Kalen JD, Hirsch JI, Kurdziel KA, Eckelman WC, Kiesewetter DO. Automated synthesis of 18F analogue of paclitaxel (PAC): [18F]paclitaxel (FPAC). Appl Radiat Isot 2007;65:696-700.
14. Kiesewetter DO, Jagoda EM, Kao CH, Ma Y, Ravasi L, Shimoji K, et al. Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. Nucl Med Biol 2003;30:11-24.
15. Ravert HT, Klecker RW, Collins JM, Mathews WB, Pomper MG, Wahl RL, et al.Radiosynthesis of [11C]paclitaxel. J Label Compd Radiopharm 2002;45:417-7.
16. van Tilburg EW, Franssen EJ, van der Hoeven JM, van der Meij M, Elshove D, Lammertsma AA, et al. Radiosynthesis of [11C]docetaxel. J Label Compd Radiopharm 2004;47:763-77.
17. van Tilburg EW, Mooijer MP, Brinkhorst J, van der Meij M, Windhorst AD. Improved and semi-Automated GMP-compliant radiosynthesis of [11C]docetaxel. Appl Radiat Isot 2008;66:1414-8.
18. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer 2002;2:683-93.
19. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009;324:1029-33.
20. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS. Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 2007;48:471-80.
21. van der Veldt AA, Smit EF, Lammertsma AA. Positron emission tomography as a method for measuring drug delivery to tumors in vivo: the example of [(11)C]docetaxel. Front Oncol 2013;3:208.
22. Verweij J, Clavel M, Chevalier B. Paclitaxel (TaxolTM) and docetaxel (TaxotereTM): not simply two of a kind. Ann Oncol 1994;5:495-505.
23. Kurdziel KA, Kalen JD, Hirsch JI, Wilson JD, Bear HD, Logan J, et al. Human dosimetry and preliminary tumor distribution of 18F-fluoropaclitaxel in healthy volunteers and newly diagnosed breast cancer patients using PET/CT. J Nucl Med 2011;52:1339-45.
24. van der Veldt AA, Lubberink M, Mathijssen RH, Loos WJ, Herder GJ, Greuter HN, et al. Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [11C]docetaxel and positron emission tomography. Clin Cancer Res 2013;19: 4163-73.
25. van der Veldt AA, Hendrikse NH, Smit EF, Mooijer MP, Rijnders AY, Gerritsen WR, et al. Biodistribution and radiation dosimetry of 11Clabelled docetaxel in cancer patients. Eur J Nucl Med Mol Imaging 2010;37:1950-8.
26. Tomasi G, Aboagye E. Introduction to the analysis of PET data in oncology. J Pharmacokinet Pharmacodyn 2013;40:419-36.
27. Gunn RN, Gunn SR, Cunningham VJ. Positron emission tomography compartmental models. J Cereb Blood Flow Metab 2001;21: 635-52.
28. Boellaard R, van Lingen A, van Balen SC, Hoving BG, Lammertsma AA. Characteristics of a new fully programmable blood sampling device for monitoring blood radioactivity during PET. Eur J Nucl Med 2001;28: 81-9.
29. van der Veldt AA, Hendrikse NH, Harms HJ, Comans EF, Postmus PE, Smit EF, et al. Quantitative parametric perfusion images using 15Olabeled water and a clinical PET/CT scanner: test-retest variability in lung cancer. J Nucl Med 2010;51:1684-90.
30. Vaclavikova R, Soucek P, Svobodova L, Anzenbacher P, Simek P, Guengerich FP, et al. Different in vitro metabolism of paclitaxel and docetaxel in humans, rats, and minipigs. Drug Metabol Dispos 2004;32:666-74.
31. van der Veldt AA, Lubberink M, Greuter HN, Comans EF, Herder GJ, Yaqub M, et al. Absolute quantification of [(11)C]docetaxel kinetics in lung cancer patients using positron emission tomography. Clin Cancer Res 2011;17:4814-24.
32. Kissel J, Brix G, Bellemann ME, Strauss LG, Dimitrakopoulou-Strauss A, Port R, et al. Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma. Cancer Res 1997;57:3415-23.
33. Kurdziel KA, Kiesewetter DO, Carson RE, Eckelman WC, Herscovitch P. Biodistribution, radiation dose estimates, and in vivo Pgp modulation studies of 18F-paclitaxel in nonhuman primates. J Nucl Med 2003;44:1330-9.
34. Bruno R, Vivier N, Veyrat-Follet C, Montay G, Rhodes GR. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs 2001;19:163-9.
35. van der Veldt AA, Lammertsma AA, Hendrikse NH. [11C]docetaxel and positron emission tomography for noninvasive measurements of docetaxel kinetics. Clin Cancer Res 2007;13:7522-3.
36. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM,Pastan I, Willingham MC. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;37:159-64.
37. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM,Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product pglycoprotein in normal human tissues. PNAS 1987;84:7735-8.
38. Huizing MT, Misser VH, Pieters RC, Bokkel Huinink WW, Veenhof CH, Vermorken JB, et al. Taxanes: a new class of antitumor agents. Cancer Invest 1995;13:381-404.
39. Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, et al. Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res 1999;90:1380-6.
40. Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007;18:v3-v8.
41. Sanson M, Napolitano M, Yaya R, Keime-Guibert F, Broet P, Hoang-Xuan K, et al. Second line chemotherapy with docetaxel in patients with recurrent malignant glioma: a phase II study. J Neurooncol 2000;50: 245-9.
42. Kemper EM, van Zandbergen AE, Cleypool C, Mos HA, Boogerd W, Beijnen JH, et al. Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin Cancer Res 2003;9:2849-55.
43. Wagner CC, Bauer M, Karch R, Feurstein T, Kopp S, Chiba P, et al. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET. J Nucl Med 2009;50:1954-61.
44. van der Veldt AA, Smit EF, Lammertsma AA. Pituitary gland: do anticancer drugs sit in the Turkish daddle? J Clin Oncol 2014;32: 851-2.
45. Kurdziel KA, Kiesewetter DO. PET imaging of multidrug resistance in tumors using 18F-fluoropaclitaxel. Curr Top Med Chem 2010;10: 1792-8.
46. Koppelmans V, Schagen SB, Poels MlMF, Boogerd W, Seynaeve C, van der Lugt A, et al. Incidental findings on brain magnetic resonance imaging in long-term survivors of breast cancer treated with adjuvant chemotherapy. Eur J Cancer 2011;47:2531-6.
47. van der Veldt AA, Smit EF, Lammertsma AA. Does drug accumulation in bone explain the efficacy and toxicity of docetaxel in prostate cancer? Clin Genitourin Cancer 2013;12:e63-4.
48. van der Veldt AA, Smit EF, Comans EF, Lammertsma AA. Effects of chemotherapy on the parotid and submandibular glands in head and neck cancer patients treated with chemoradiotherapy. Strahlenther Onkol 2014;190:221-2.
49. Burris H, Irvin R, Kuhn J, Kalter S, Smith L, Shaffer D, et al. Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion. J Clin Oncol 1993;11:950-8.
50. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000;31:578-83.
51. van der Veldt AA, Smit EF, Lammertsma AA. Cancer therapy: could a novel test predict the amount of drug that reaches its target? Expert Rev Anticancer Ther 2013;13:377-9.
52. Latreille J, Gelmon KA, Hirsh V, Laberge F, Maksymiuk AW, Shepherd FA, et al. Phase II trial of docetaxel with dexamethasone premedication in patients with advanced non-small cell lung cancer: the Canadian experience. Invest New Drugs 1999;16:265-70.
53. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, Coleman R, et al. Corticosteroids significantly delay the onset of docetaxelinduced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15:3149-55.
54. Lappin G, Garner RC. Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat Rev Drug Discov 2003;2:233-40.
55. Bergstrom M, Grahnen A, Langstrom B. Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development. Eur J Clin Pharmacol 2003;59: 357-66.
56. Harte RJ, Matthews JC, O'Reilly SM, Tilsley DW, Osman S, Brown G, et al. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-Aspartate, folinic acid, and interferon alfa. J Clin Oncol 1999;17:1580-8.
57. Propper DJ, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J, et al. Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000. J Clin Oncol 2003;21:203-10.
58. Saleem A, Harte RJ, Matthews JC, Osman S, Brady F, Luthra SK, et al. Pharmacokinetic evaluation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in patients by positron emission tomography. J Clin Oncol 2001;19:1421-9.
59. Solbach C, Patt M, Reimold M, Blocher A, Dohmen BM, Bares R, et al. [11C]Vinblastine syntheses and preliminary imaging in cancer patients. J Pharm Pharm Sci 2007;10:266s-76s.
60. Hsueh WA, Kesner AL, Gangloff A, Pegram MD, Beryt M, Czernin J, et al. Predicting chemotherapy response to paclitaxel with 18F-fluoropaclitaxel and PET. J Nucl Med 2006;47:1995-9.
61. Jain RK. Normalizing tumor vasculature with antiangiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
62. van der Veldt AA, Lubberink M, Bahce I, Walraven M, de Boer MP, Greuter HN, et al. Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of antiangiogenic drugs. Cancer Cell 2012;21:82-91.
63. van der Veldt AA, Lammertsma AA, Smit EF. Scheduling of anticancer drugs: timing may be everything. Cell Cycle 2012;11:4339-43.
64. van der Veldt AA, Smit EF. Bevacizumab in neoadjuvant treatment for breast cancer. N Engl J Med 2012;366:1637-40.
65. Casanovas O. Cancer: limitations of therapies exposed. Nature 2012; 484:44-6.
66. Hohl RJ. Personalized medicine: through the looking glass of functional imaging. Clin Cancer Res 2013;19:4024-6.
67. Kurdziel KA, Kalen JD, Hirsch JI, Wilson JD, Agarwal R, Barrett D, et al. Imaging multidrug resistance with 4-[18F]fluoropaclitaxel. Nucl Med Biol 2007;34:823-31.
68. Gainor JF, Longo DL, Chabner BA. Pharmacodynamic biomarkers: falling short of the mark? Clin Cancer Res 2014;20:2587-94.
69. Hertz DL, McLeod HL. Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology. Clin Cancer Res 2014;20:2530-40.
70. Low S-K, Takahashi A, Mushiroda T, Kubo M. Genome-wide association study: a useful tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. Clin Cancer Res 2014;20:2541-52.
71. Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 2014;20: 2553-68.
72. Aboagye EO, Luthra SK, Brady F, Poole K, Anderson H, Jones T, et al. Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br J Cancer 2002;86:1052-6.